Infectious hepatitis in HIV-seropositive patients

International Journal of STD and AIDS

Volumn 9, Issue 2, 1998, Pages 63-69

  Newell, A ^a   Nelson, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Delta; Hepatitis A,B,C; HIV; Treatment; Vaccination

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; DIDANOSINE; FAMCICLOVIR; HEPATITIS B VACCINE; LAMIVUDINE; PENCICLOVIR; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG RESPONSE; HEPATITIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

EID: 0031906657     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462981921648     Document Type: Review

References (116)

1. Christenson B, Bronstom CH, Bottinger M, et al. An epidemic outbreak of hepatitis A among homosexual men in Stockholm. Am J Epidemiol 1982;116:599-607
2. Leentvaar-Kuijpers A, Kool JL, Veugelers PJ, et al. An outbreak of hepatitis A among homosexual men in Amsterdam 1991-1993. Int J Epidemiol 1995;24(1):218-22
3. Nandwani R, Caswell S, Boag F, et al. Hepatitis A seroprevalence in homosexual and heterosexual men. Genitourin Med 1994;70:325-8
4. Lucht F, Berthelot P, Job P, et al. Seroprevalence of viral hepatitis A in France in homosexuals and intravenous drug users. Presse Médicale 1996;25(25):1141-3
5. Laskus T, Radkowski M, Lupa E et al. Markers of hepatitis A infection in drug addicts. Pol Tyg Lek 1993;48:261-2
6. Kumar A, Kulkarni R, Murray DL, et al. Serologic markers of viral hepatitis A, B, C, and D, in patients with haemophilia. J Med Virol 1993;41:205-9
7. Olson P, Kennedy C. The incidence, clinical manifestations and severity of hepatitis A in US HIV infected personnel (Abstract P0-B08-1331). International Conference on AIDS 6-11 June 1993
8. Hess G, Clemens R, Bienzle U, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995;46(1):40-2
9. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9
10. Glesby MJ, Hoover DR, Farazadegan H, et al. The effect on influenza vaccination on human immunodeficiency virus type 1 load: a randomised, double-blind, placebo-controlled study. J Infect Dis 1996;174:1332-6
11. Homann C, Krogsgaard K, Pedersen C, et al. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J AIDS 1991;4:416-20
12. Kashala O, Mubikayi L, Kayembe K, et al. Hepatitis B virus activation among central Africans infected with human immunodeficiency virus (HIV) type 1: pre-s2 antigen is predominantly expressed in HIV infection. J Infect Dis 1994;169:628-32
13. Hadler C. Hepatitis B prevention and human immunodeficiency virus (HIV) infection. Ann Intern Med 1988;109: 92-4
14. Collier A, Corey L, Murphy V, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988;109:101-5
15. Carne CA, Weller IVD, Waite J, et al. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. BMJ 1987;294:866-8
16. Mannucci PM, Zanetti AR, Gringeri A. Long-term immunogenicity of a plasma derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med 1989;149:1333-7
17. Odaka N, Eldred L, Cohn S, et al. Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. J Am Med Assoc 1988;260:3635-7
18. Bruguera M, Cremades M, Salinas R, et al. Impaired response to recombinant hepatitis B vaccine in HIV infected persons. J Clin Gastroenterol 1992;14:27-30
19. Tayal SC, Sanker KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV infected individuals. AIDS 1994;8:558-9
20. Biggar R, Goedert J, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987;316:630-1
21. Arrazola MP, de Juanes JR, Ramos JT, et al. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol 1995;45(3):339-41
22. Department of Health. Immunisation Against Infectious Diseases. London: HMSO, 1996:97
23. Hadler S, Judson F, O'Malley P, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-9
24. Zuckermann JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997;314:329-33
25. Cheeseman SH, Davaro RE, Ellison RT. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med 1996;334:1272
26. Bodsworth N, Cooper D, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40
27. Trent Mills C, Lee E, Perrillo R. Relationship between histology, aminotransferase levels and viral replication in chronic hepatitis B. Gastroenterology, 1990;99:519-24
28. Goldin RD, Fish DE, Hay A, et al. Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 1990;43:203-5
29. Perrillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 1986;105:382-3
30. Krogsgaard K, Lindhardt BO, Nielson JO, et al. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 1987;7:37-41
31. McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant α-interferon. Hepatology 1987;7:719-23
32. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-82
33. Koblin BA, Taylor PE, Rubinstein P, Stevens CE. Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type 1 and hepatitis B viral replication. Hepatology 1992;15:590-2
34. Vento S, di Perri G, Luzzati R, et al. Clinical reactivation of hepatitis B in anti-HBs positive patients with AIDS. Lancet 1989:1:332-3
35. Gilson RJC, Tedder RS, Weller IVD. Hepatitis B: reactivation or reinfection associated with HIV-1 infection. Lancet 1989;1:1330
36. Waite J, Gilson JC, Weller IVD, et al. Hepatitis B virus reactivation of reinfection associated with HIV-1 infection. AIDS 1988;2:443-8
37. Sheron N, Lau J, Daniels H, et al. Increased production of tumour necrosis factor alpha in chronic hepatitis B infection. J Hepatol 1991;12:241-5
38. Israel N, Hazan U, Alcami J, et al. Tumour necrosis factor stimulates transcription of HIV-1 in human T-lymphocytes independently and synergistically with nitrogens. J Immunol 1989;143:3956-60
39. Clouse KA, Robbins PA, Fernie B, et al. Viral antigen stimulation of the production of human monokines capable of regulating HIV-1 expression. J Immunol 1989;143:470-5
40. Eskild A, Magnus P, Petersen G, et al. Hepatitis B antibodies in HBV infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992;6:571-4
41. Scharchmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992;117:837-8
42. Solomon RE, Van Raden M, Kaslow RA, et al. Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Am J Public Health 1990;80:1475-8
43. Wong DKH, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomised trial in a predominantly homosexual male population. Gastroenterology 1995;108:165-71
44. Marcellin P, Boyer N, Colin JF, et al. Recombinant alpha interferon for chronic hepatitis B in anti HIV positive patients receiving zidovudine. Gut 1993;34(suppl):S106
45. Marcellin P, Pialoux G, Girard PM, et al. Absence of effect of zidovudine on replication of hepatitis B virus in patients with chronic HIV and HBV infection. N Engl J Med 1989;321:1758
46. di Martino V, Lunel F, Cadranel JF, et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepatol 1996;3:253-60
47. Kossianides C, Hoofnagle J, Miller R, et al. Inhibition of duck hepatitis B virus replication by 2,3-dideoxyinosine: a potent inhibitor of reverse transcriptase. Gastroenterology 1989;97:1275-80
48. Catterall AP, Moyle GJ, Hopes EA, et al. Dideoxyinosine for chronic hepatitis B infection. J Med Virol 1992;37:307-9
49. Fried MW, Korenman JC, Di Bisceglie AM, et al. A pilot study of 2,3-dideoxyinosine for the treatment of chronic hepatitis B. Hepatology 1992;16:861-4
50. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996;62(10):1456-62
51. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-15
52. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61
53. Lai C-L, Ching C-K, Tung AK-M, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25:241-4
54. Honkoop P, de Man RA, Heijtink RA, Schalm SW. Hepatitis reactivation after lamivudine. Lancet 1995;346:1156-6
55. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependant DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-17
56. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-13
57. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthoptic liver transplantation. Lancet 1997;349: 20-2
58. Sinclair FJ, Womack M, Illeman M, et al. Benefits and safety of lamivudine (3TC) therapy in HIV-positive patients with chronic hepatitis B or C (Abstract Tu. B.2131). XI International Conference on AIDS, Vancouver 1996
59. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125(9)705-12
60. Schnittman SM, Pierce PF. Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type 1. Clin Infect Dis 1996;23:638-9
61. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996;24:991-5
62. Arends S, van Halteren E, Kamp W, Schokker J. Safety of 9-(2-phosphonylmethoxyethyl-adenine (PMEA) in patients with human immunodeficiency virus infection. Pharm World Sci 1996;18:30-4
63. mne infection in macaques. J Med Primatol 1994;23:175-83
64. Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993;21:141-53
65. Gilson R, Chopra K, Murray-Lyon I, et al. A placebo controlled phase I/II study of Adefovir Dipivoxil (Bis-POM PMEA) in patients with chronic hepatitis B infection (Abstract). Hepatology 1996;24:281A
66. Boker KHW, Ringe B, Kruger M, et al. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994;57(12):1706-8
67. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996;24:996-1002
68. Schalm SW, de-Man RA, Heijtink RA, Niesters HG. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995;22(1 Suppl):52-6
69. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997;26:216-25
70. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in an HIV-infecced patient on protease inhibitor. Lancet 1997;349:995-6
71. Kelen GD, Green GB, Purcell RH, et al. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med 1992;326:1399-404
72. Ranger S, Aussel L, Weinbreck P, et al. Seroprevalence of hepatitis C in human immunodeficiency virus infected patients. Pathol Biol 1991;39:126-30
73. Quaranta JF, Delaney SR, Alleman S, et al. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1 infected patients. J Med Virol 1994;42:29-32
74. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patient with and without AIDS prevalence and relationship to patient survival. Hepatologgy 1994;20:1152-5
75. Eyster EM, Harvey J, Aledort JM, et al. Heterosexual cotransmission of hepatitis C virus (HCV) and human deficiency virus (HIV). Ann Intern Med 1991;115:764-8
76. Giovanni M, Tagger A, Ribero ML, et al. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990;335:1166
77. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995;345:289-91
78. Martin P, Di Bisceglie AM, Kassianides C, et al. Rapidly progressive non-A non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989;97:1559-61
79. Libanore M, Bicocchi R, Sighinolfi L, et al. Fulminant NANB hepatitis in a patient involved with AIDS: a possible demonstration of direct hepatic damage by the virus(es) involved. Infection 1988;16:255
80. Eyster EM, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of co-infection with human immunodeficiency virus. J AIDS 1993;6:602-10
81. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to HIV infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-3
82. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5
83. Soriano V, Bravo R, Mas A, et al. Hepatitis C viraemia in HIV-infected patients. AIDS 1996;10:922-3
84. Ghany MG, Leissinger C, Lagier R, et al. Effect of human immunodeficiency virus infection on hepatitis C virus infection on hepatitis C virus infection in haemophiliacs. Dig Dis Sci 1996;41:1265-72
85. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response on patients infected with HIV. AIDS 1995;9:1131-6
86. Richard L, Pellegrin JL, Barbeau P. HIV-1 and HCV co-infected patients: detection of active viral expression using a nested polymerase chain reaction. Mol Cell Probes 1993;7:405-10
87. Telfer PT, Brown D, Devereux H, et al. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 1994;88:397-9
88. Berger A, Depka Prondzinski MV, Doerr HW, et al. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 1996;48:339-43
89. Llibre JM, Garcia E, Aloy A, Valls J. Hepatitis C virus and progression of infection due to human immunodeficiency virus. Clin Infect Dis 1993;16:182
90. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1993;17:117-19
91. Dorrucci M, Pezzotti P, Phillips AN, et al. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. J Infect Dis 1995;172:1503-8
92. Sabin C, Telfer P, Phillips AN, et al. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997;175:164-8
93. Marriott E, Navas S, del Romeo J, et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993;40:107-11
94. Mauss S, Heintges T, Adams O, et al. Treatment of chronic hepatitis C with interferon-α in patients infected with human immunodeficiency virus. Hepato-Gastroenterol 1995;42:528-34
95. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-α for chronic hepatitis C in patient positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165:723-6
96. Soriano V, Samaniego JG, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996;23:585-91
97. Cribier B, Schmitt C, Rey D, et al. Role of endogenous interferon in hepatitis C virus (HCV) infection and coinfection by HIV and HCV. Res Virol 1996;147:263-6
98. Soriano V, Bravo R, Samaniego JG, et al. CD4+ T-lymphocytopenia in HIV-infected patient receiving interferon therapy of chronic hepatitis C. AIDS 1994;8:1621-34
99. Pesce A, Rosenthal E, Vinti H, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993;341:1597
100. Vento S, Di Perri G, Cruciani M, et al. Rapid decline of CD4+ cells after IFNα treatment in HIV-1 infection. Lancet 1993;341:958
101. Takano S, Ito Y, Yokosuka A, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-64
102. Filocamo G, Pacini L, Migliaccio G. Chimeric sindbis viruses dependent on the NS3 protease of hepatitis C virus. J Virol 1997;71:1417-27
103. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-55
104. Housett C, Pol S, Carrot F, et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992;15:578-83
105. Novick DM, Farci P, Croxson TS, et al. Hepatitis D virus and human deficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. J Infect Dis 1988;158:795-803
106. Buti M, Estaban R, Espanol MT, et al. Influence of human immunodeficiency virus infection on cell-mediated immunity in chronic D hepatitis. J. Infect Dis 1991;163:1351-3
107. Kreek MJ, Des Jarlais DC, Trepo CL, et al. Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. J Infect Dis 1990;162:538-41
108. Roingeard P, Dubois F, Marcellin P, et al. Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection. J Med Virol 1992;39:191-4
109. De Pouplana M, Soriano V, Samaniego JG, et al. More severe course of delta hepatitis in HIV-infected patients. Genitourin Med 1995;71:132-3
110. Pol S, Wesenfelder L, Dubois F, et al. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepatol 1994;1:131-7
111. Lichenstein DR, Makadon HJ, Chopra S. Fulminant hepatitis B and delta viruses co-infection in AIDS. Am J Gastroenterol 1992;87:1643-7
112. Taillan B, Fuzibet J-G, Vinti H, et al. Interferon and delta hepatitis. Ann Intern Med 1988;109:760
113. Krogsgaard K, Kryger P, Aldershvile J, et al. Delta-infection and suppression of hepatitis B virus replication in chronic HBsAg carriers. Hepatology 1987;7:42-5
114. Farci P, Manda A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94
115. Buti M, Jardi R, Allende H, et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol 1996;49:66-9
116. Eyster ME, Sanders JC, Battegay M, et al. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Dig Dis Sci 1995;40:1583-8